- Home
- PCRX vs MAX Comparison
PCRX vs MAX Comparison
Compare PCRX & MAX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PCRX
- MAX
- Stock Information
- Founded
- PCRX 2006
- MAX 2014
- Country
- PCRX United States
- MAX United States
- Employees
- PCRX N/A
- MAX N/A
- Industry
- PCRX Biotechnology: Pharmaceutical Preparations
- MAX Industrial Machinery/Components
- Sector
- PCRX Health Care
- MAX Industrials
- Exchange
- PCRX Nasdaq
- MAX Nasdaq
- Market Cap
- PCRX 1.2B
- MAX 551.1M
- IPO Year
- PCRX 2011
- MAX 2020
- Fundamental
- Price
- PCRX $21.97
- MAX $12.72
- Analyst Decision
- PCRX Strong Buy
- MAX Buy
- Analyst Count
- PCRX 5
- MAX 6
- Target Price
- PCRX $33.00
- MAX $17.00
- AVG Volume (30 Days)
- PCRX 696.0K
- MAX 604.4K
- Earning Date
- PCRX 11-06-2025
- MAX 10-29-2025
- Dividend Yield
- PCRX N/A
- MAX N/A
- EPS Growth
- PCRX N/A
- MAX N/A
- EPS
- PCRX 0.47
- MAX N/A
- Revenue
- PCRX $716,791,000.00
- MAX $1,123,093,000.00
- Revenue This Year
- PCRX $7.27
- MAX $31.14
- Revenue Next Year
- PCRX $10.18
- MAX $9.79
- P/E Ratio
- PCRX $46.78
- MAX N/A
- Revenue Growth
- PCRX 3.14
- MAX 64.86
- 52 Week Low
- PCRX $16.00
- MAX $7.33
- 52 Week High
- PCRX $27.64
- MAX $13.85
- Technical
- Relative Strength Index (RSI)
- PCRX 44.53
- MAX 60.40
- Support Level
- PCRX $21.20
- MAX $12.14
- Resistance Level
- PCRX $22.70
- MAX $13.85
- Average True Range (ATR)
- PCRX 1.25
- MAX 0.57
- MACD
- PCRX 0.13
- MAX 0.17
- Stochastic Oscillator
- PCRX 51.44
- MAX 62.82
About PCRX Pacira BioSciences Inc.
Pacira BioSciences Inc is a provider of non-opioid pain management and regenerative health solutions dedicated to advancing and improving outcomes for healthcare practitioners and their patients. The company's commercialized non-opioid treatments: EXPAREL a long-acting, local analgesic currently approved for postsurgical pain management; ZILRETTA, an extended-release, intra-articular, corticosteroid injection indicated for the management of osteoarthritis; and iovera, a novel, handheld device for delivering immediate, long-acting, drug-free pain control using precise, controlled doses of cold temperature to a targeted nerve. In addition, it is developing PCRX-201 (enekinragene inzadenovec), a novel gene therapy vector platform for the treatment of osteoarthritis of the knee.
About MAX MediaAlpha Inc.
MediaAlpha Inc provides a platform that facilitates insurance carriers and distributors target and acquire customers. The company's technology platform brings insurance carriers and consumers together through a real-time, transparent, and results-driven ecosystem. It acts as a customer acquisition channel in the areas of property & casualty insurance, health insurance, and life insurance. It operates in the United States and generates revenue by earning a fee for each consumer referral sold on its platform.